G Protein-coupled receptors and their signaling pathways: Classical therapeutical targets susceptible to novel therapeutic concepts

Current Pharmaceutical Design

Volumn 10, Issue 16, 2004, Pages 1937-1958

  Liebmann, Claus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

G protein couple receptors; Isozymes; Novel modifying proteins; Signaling pathways; Subtypes; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ADENYLATE CYCLASE; ANTIMIGRAINE AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SENSING RECEPTOR; CILOMILAST; CL 1040; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTRANSMITTER; NIGULDIPINE; PEPTIDE DERIVATIVE; PHENOXYBENZAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV INHIBITOR; PRAZOSIN; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR SUBTYPE; RHODOPSIN; ROFLUMILAST; SECRETIN; SILDENAFIL; TAMSULOSIN; TIPIFARNIB; UNINDEXED DRUG;

ASTHMA; BINDING SITE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEGRADATION; DIMERIZATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; MIGRAINE; MODULATION; MOLECULAR BIOLOGY; NARCOLEPSY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; VOMITING;

ANIMALS; DRUG DELIVERY SYSTEMS; GTP-BINDING PROTEINS; HUMANS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 2442474029     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384367     Document Type: Review

References (172)

1. Howard AD, et al. Orphan G protein-coupled receptors and natural ligand discovery. Trends Pharmacol Sci 2001; 22: 132-40.
2. Hopkins AL, Groom CR.Tke druggable genome. Nat Rev Drug Discov 2002; 1-727-30.
3. Menzaghi F, Behau DP, Chalmers DT. Constitutive activated G protein-coupled receptors: a novel approach to CNS drug discovery. Curr Drug Target CNS Neurol Disord 2002; 1: 105-21.
4. Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. Cell 2000; 103: 211-25.
5. Yarden Y, Sliwkowski MX. Undertangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
6. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
7. Downward J. Targeting Ras Signalling Pathways in Cancer Therapy. Nat Rev 2003; 3: 11-22.
8. Hoshino R. et al. Constitutive activation of the 41-/43- kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22.
9. Ciardillo F, Tortora G. A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor receptor. Clin Cancer Res 2001; 7: 2958-70.
10. Heldin CH. Signal Transduction: Multiple Pathways, Multiple Options for Therapy. Stem Cells 2001; 19: 295-303.
11. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocrine-related Cancer 2001, 8: 3-9.
12. Zwick F, Bange J, Ullrich A. receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-Related Cancer 2001; 8: 161-73.
13. Baselga J, Hammond LA. HER-Targeted Tyrosine-Kinase Inhibition. Oncology 2002; 63 (Suppl. 1): 6-16.
14. English JM, Cobb MH. Pharmacological Inhibition of MAPK pathways. Trends Pharmacol Sci 2002; 23: 40-45.
15. Lee AV, et al. New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transduction. Clin Canc Res 2003, 9 (suppl): 516-23.
16. Dancey J, Sansville EA. Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment. Nat Rev 2003; 2: 296-313.
17. Sebolt-Leopold JS, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat med 1999, 5: 810-815.
18. Gudermann T, Kalkbrenner F, Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu Rev Pharm Tox 1996; 36: 429-59.
19. Bourne H. How receptor talk to trimeric G proteins. Curr Opin Cell Biol 1997; 9: 134-42.
20. Ji TH, Grossmann M, Ji I. G protein-coupled receptors: I. Diversity of receptor ligand interaction. J Biol Chem 1999, 237: 17299-302.
21. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocrinol Rev 2000; 21: 90-113.
22. Pierce KL, Premont RT, Lewfkowitz RJ. Seven-Transmembrane Receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50.
23. George SR, O'Dowd BF, Lee SP. G-Protein-Coupled Receptor Oligomerization and its Potential for Drug Discovery. Nat Rev Drug Disc 2002; 1: 808-20.
24. Wong SKF. G Protein Selectivity is regulated by Multiple Intracellular Regions of GPCRs. Neurosignals 2003; 12: 1-12.
25. Venter JC, et al. Sequence of the human genome. Science 2001; 291: 1304-50.
26. Carafoli E. Calcium signaling. A tale for all seasons. Proc Natl Acad Sci USA 2002; 99: 115-22.
27. Newton AC, Johnson JE. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting molecules. Biochim Biophys Acta 1998; 1376: 155-72.
28. Ferguson SG. Evolving Concepts in G Protein-Coupled Receptor Endocytosis: The Role in receptor Desensitization and Signaling. Pharmacol Rev 2001; 53: 1-24.
29. Selbie LA, Hill SJ. G protein-coupled-receptor cross-talk: The fine tuning of multiple receptor-signalling pathways. Trends Pharmacol Sci 1998; 19: 87-93.
30. Cordeaux Y, Hill SJ. Mechanisms of Cross-Talk between G-Protein-Coupled Receptors. Neurosignals 2002; 11: 45-57.
31. Hur EM, Kim KT. G protein-coupled signalling and cross-talk achieving rapidity and specificity. Cellular Signalling 2002; 14: 397-405.
32. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700.
33. Offermanns S, Schultz G. Complex information processing by the transmembrane signaling system involving G proteins. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350: 329-38.
34. 2-adrenergjc receptor to different G proteins by protein kinase A. Nature 1997; 390: 88-91.
35. 2 Receptors Results in Cooperative Regulation of Cyclic AMP Accumulation and Mitogen-Activated Protein Kinase Activity. Mol Cell Biol 2001; 21: 8452-60.
36. Gutkind JS. The pathways connecting G protein-coupled rceptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998; 273: 159-61.
37. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity. Cellular Signalling 2001; 13: 777-85.
38. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001; 20: 1594-1600.
39. Belcheva MM, Coscia CJ. Diversity of G Protein-Coupled Receptor Signalimg Pathways to ERK/MAP Kinase. Neurosignals 2002; 11: 34-44.
40. Luttrell LM. G Protein-Coupled Receptor Signalling in Neuroendocrine Systems. "Location, location, location": activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinel 2003; 30: 117-126.
41. Wetzker R, Böhmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 2003; 4: 1-6.
42. Schmitt JM, Stork PJS. Gα and Gβγ require distinct Src-dependent pathways to activate Rap1 and Ras. J Biol. Chem 2002; 277: 43024-43032.
43. Bos JL. Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 2003; 4: 733-38.
44. Schönwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998; 18: 790-98.
45. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G protein-coupled receptors with MAP kinase activation. Nature 1996; 383: 547-50.
46. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors require metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-88.
47. Bhalla US, Iyengar R. Emerging properties of networks of biological signaling pazhways. Science 1999, 283: 381-87.
48. Jordan JD, Landau EM, Iyengar R. Signaling networks: the origin of cellular multitasking Cell 2000; 103: 193-200.
49. Neves SR, Iyengar R. Modeling of signaling networks. BioEssays 2002; 24: 1110-17.
50. Brophy JM, Joseph L, Rouleau JL. βBlockers in congestive heart failure. A Bayersian meta-analysis. Ann Intern Med 2001; 134: 550-60.
51. Garcia-Sainz JA, Vazques-Prado J, del Carmen Medina L. Alpha 1-adrenoceptor function and phosphorylation. Eur J Pharmacol 2000; 389: 1-12.
52. Varma DR, Deng XF. Cardiovascular alpha 1-adrenoceptor subtyps: functions and signaling. Can J Physiol Pharmacol 2000; 78: 267-92.
53. 1-Adrenergic Receptors: New Insights and Directions. J Pharmacol Exp Ther 2001; 298: 403-10.
54. 1-Adrenoceptor Pharmacology. Biol Pharm Bull 2002; 25: 401-08.
55. Hawes BE, van Biesen T, Koch WJ, Luttrell LM, Letkowitz RJ. Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation. J Biol Chem 1995; 270: 17148-53.
56. Thiyagarajan M. α-Adrenoceptor Antagonists in the Treatment of Benign Prostate Hyperplasia. Pharmacology 2002; 65: 119-28.
57. Willems EW, Valdivia LF, Villalon CM, Saxena PR. Possible role of α-adrenoceptor subtypes in acute migraine therapy. Cephalagia 2003; 23: 245-57.
58. 2B-adrenergici receptor in the development of salt-induced hypertension. Hypertension 1999; 33: 14-7.
59. 2-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regulatory Integrative Comp Physiol 2002; 283: R297-95.
60. 2-Adrenergic Agonists. Anesthesiology 2000; 93: 1345-9.
61. 2-Adrenoceptor agonists in anaesthesia: a new paradigm. Curr Op Anesthesiol 2000; 13: 437-42.
62. 2A adrenoceptor subtype to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J Clin Invest 1996; 98: 1076-80.
63. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat rev Drug Disc 2002; 1: 198-210.
64. Christopoulos A, Kenakin T. G Protein-Coupled Receptor Allosterism and Complexing. Pharmacol rev 2002; 54: 323-74.
65. 2+. Mol Pharmacol 2002; 61: 65-72.
66. 2 dopamine receptors. J Neurochem 1997; 68: 1990-97.
67. 2A-adrenoceptor: allosteric modulation by amilorids. Mol Pharmacol 2000; 58: 1091-99.
68. Thomas EA, Canson MJ, Neal MJ, Sutcliffle JG. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 1997, 94: 14115-19.
69. Fillion G, et al. A new peptide, 5-HT-moduline, isolated and purified form mammalian brain specifically interacts with 5-HT1B/1D receptors. Behav Brain Res 1996; 73: 313-17.
70. Stirnweiss J, Hartrodt B, Greksch G, Stürzebecher U, Böhmer FD, Neubert K, Liebmann C. Tyr-c[D-Orn-Tyr(Bzl)-Pro Gly]: a novel antiproliferative acting somatostatin receptor agonist with μ-opioid receptor-sensitizing properties. Brit J Pharmacol 2003; 140: 13-22.
71. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled dimerization: modulation of receptor function. Pharmacology & Therapeutics 2001; 92: 71-87.
72. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cell Signal 2002; 14: 297-309.
73. McLatchie LM, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333-39.
74. Fischer JA, Muff R, Born W. Functional relevance of G-protein-coupled-receptor-associated proteins, exemplified by receptor-activity-modifying proteins (RAMPs). Biochem Soc Trans 2002; 4: 455-60.
75. Born W, Fischer JA, Muff R. Receptors for calcitonin gene-related peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity-modifying proteins. Receptor Channels 2002; 8: 201-9.
76. Flahaut M, Rossier BC, Firsov D. Respective Roles of Calcitonin Receptor-like Receptor (CRLR) and Receptor Activity-modifying Proteins (RAMP) in Cell Surface Expression of CRLR/RAMP Heterodimeric Receptors. J Biol Chem 2002, 277: 14731-7.
77. Kikumoto K, Katafuchi T, Minamino N. Specificity of porcine calcitonin receptor and calcitonin receptor-like receptor in the presence of receptor-activity-modifying proteins. Hypertens Res 2003; 26: S15-23.
78. Kuwasako K, Kitamura K, Nagoshi Y, Cao YN, Eto T. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J Biol Chem 2003; 278: 22623-30.
79. Christopoulos A, et al. Novel Receptor Partners and Function of Receptor Activity-modifying Proteins. J Biol Chem 2003, 278: 3293-7.
80. Shaaban S, Benton B. Orphan G protein-coupled receptors: from DNA to drug targets. Curr Opin Drug Discov Devel 2001; 4: 535-47.
81. Menzaghi F, Behan DP, Chalmers DT. Constitutively activbated G protein-coupled receptors: a novel approach to CNS drug discovery. Curr Drug Target CNS Neurol Disord 2002; 1: 104-21.
82. Katugampola S, Davemport A. Emergine roles for orphan G-protein-coupled recetors in the cardiovascular system. Trends Pharmacol Sci 2003; 24 : 30-5.
83. Wilson S, et al. Orphan G-protein-coupled receptors: the next generation of drug targets? Brit J Pharmacol 1998; 125: 1387-92.
84. Milligan G. Strategies to identify ligands for orphan G-protein-coupled receptors. Biochem Soc Transact 2002; 30: 789-93.
85. Davenport AP. Peptide and trace amine orphan receptors: prospects for new therapeutic targets. Curr Opin Pharmacol 2003; 3: 127-34.
86. Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour. Cell 1998; 92: 573-85.
87. Beuckmann CT, Yanagisawa M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 2002; 80: 329-42.
88. Karteris E, Randevy HS. Orexin Receptors and G-Protein Coupling: Evidence for Another "Promiscuous" Seven Transmembrane Domain Receptor. J Pharmacol Sci 2003; 93: 126-8.
89. Amers RS, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-6.
90. Tatemoto K, et al. Isolation and characterization of a novel endogenous pwptide ligand for the human APJ receptor. Biochem Biophys Res Common 1998; 251: 471-6.
91. Kojima M, Hosoda H, Date Y, Nakazato M, Kanagawa K. Ghrelin is a growth-hirmone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
92. Maguire M, Davenport AP. Is urotensin II the new endothelin? Brit J Pharmacol 2002; 137: 579-88.
93. Katagampola SD, Kuc RE Maguire JJ, Davenport AP. G-protein-coupled receptors in human artherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently deorphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci 2002; 103: 171S-5S.
94. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 1996; 48: 1210-25.
95. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 366: 381-416.
96. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003; 8: 1093-108
97. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15: 598-611.
98. Strange PG. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 2002, 23: 89-95.
99. 2Λ receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001; 299: 268-76.
100. 1-receptor transgenic mice. Mol Pharmacol 2001; 60: 712-17.
101. Rosenkilde MM, Schwartz TW. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol 2000; 57: 602-9.
102. Coward P, Chan SD, Wada HG, Humphries GM, Conklin BR. Chimeric G proteins allow a high-throughput signaling assay of Gicoupled receptors. Anal Biochem 1999; 270: 242-8.
103. Scearce-Levie K, Coward P, Redfern CH, Conklin BR. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol Sci 2001; 22: 414-20.
104. Coward P, Wada HG, Falk MS, Chan SDH, Meng F, Akil H, Conklin BR. Controlling signaling with a specifically designed Gicoupled receptor. Proc Natl Acad Sci USA 1998; 95: 352-7.
105. Small KM, Brown KM, Forbes SL, Liggett SB. Modification of the beta 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. J Biol Chem 2001; 276: 31596-601.
106. Srinivasan S, Vaisse C, Conklin BR. Engineering the melanocortin-4 receptor to control G(s). Ann NY Acad Sci 2003; 994: 225-32.
107. s-coupled Receptor Activated Exclusively by Synthetic Ligands (RASSL). J Biol Chem 2003; 278: 699-702.
108. Galeotti N, Ghelardini C, Bartolini A. Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein α-subunits. Brit J Pharmacol 2001; 133: 267-74.
109. Cismowski MJ, et al. Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling. Nature Biotechnol 1999; 17: 878-83.
110. Takesono A, et al. Receptor-independent Activators of Heterotrimeric G-protein Signaling Pathways. J Biol Chem 1999; 274: 33202-5.
111. Ma H, Perterson YK, Bernard ML, Lanier SM, Graber SG. Influence of Cytosolic AGS3 on Receptor-G Protein Coupling. Biochemistry 2003; 42: 8085-93.
112. Blumer JB, et al. Interaction of Activator of G-protein Signaling 3 (AGS3) with LKB1, a Serine/Threonine Kinase Involved in Cell Polarity and Cell Cycle Progression. J Biol Chem 2003; 278: 23217-20.
113. Scott JK, et al. Evidence that a protein-protein interaction 'hot spot' on heterotrimeric G protein betagamma subunits is used for recognition of a subclass of effectors. EMBO J 2001; 20: 767-76.
114. Goubaeva F, et al. Stimulation of Cellular Signaling and G Protein Subunit Dissociation by G Protein βγ Subunit-binding Peptides. J Biol Chem 2003; 278: 19634-41.
115. Ghosh M, Peterson YK, Lanier SM, Smreka AV. Receptor- and Nucleotide Exchange-indeperident Mechanisms for Promoting G Protein Subunit Dissociation. J Biol Chem 2003; 278: 34747-50.
116. Neubig RR, Siderovski DP. Regulators of G-protein signaling as new central nervous system drug targets. Nature Rev Drug Discov 2002; 11: 187-97.
117. Kozasa T, et al. P115RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 1998; 280: 2109-11.
118. Huang LS, Durick K, Weiner JA, Chun J, Taylor SS. D-AKAP2, a novel protein kinase anchoring protein with a putative RGS domain. Proc Natl Acad Sci USA 1997; 94: 11184-9.
119. Wedegaertner PB, Gilman AG, Benovic JL, Kozasa T. Selective regulation of Galpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 1999; 274: 34483-92.
120. Hooks SB, Waldo GL, Corbitt J, Bodor ET, Krumins AM, Harden TK. RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity. J Biol Chem 2003; 278: 10087-93.
121. Cho H, Harrison K, Schwartz O, Kehrl H. The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling. Biochem J 2003; 371: 973-80.
122. Rahman Z, et al. RGS9 Modulates Dopamine Signaling in the Basal Ganglia. Neuron 2003; 38: 941-52.
123. Zhong H, Neubig RR. Regulators of G Protein Signaling Proteins: Novel Multifunctional Drug Targets. J Pharmacol Exp Ther 2001; 297: 837-45.
124. Popov SG, Krishna UM, Falk JR, Wilkie TM. Ca2+/calmodulin reverses phsophatidylinositol 3,4,5-trisphosphate-dependent inhibition of regulators of G protein-signaling GTPase-activating protein activity. J Biol Chem 2000; 275: 18962-8.
125. Rhee SG, Bae YS. Regulation of Phosphoinositide-specific Phospholipase C Isozymes. J Biol Chem 1997; 273: 15045-8.
126. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 2003; 370: 361-71.
127. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 2001; 20: 6339-47.
128. Vivanco I, Sawyers CL. The Phosphatidylinositol 3-Kinase-Akt Pathway in Human Cancer, Nat Rev Cancer 2002; 2: 489-501.
129. Crackower MA, et al. Regulation of Myocardial Contractility and Cell Size by Distinct P13K-PTEN Signaling Pathways. Cell 2002; 110: 737-49.
130. Defer N, Best-Belpomme M, Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Renal Physiol 2000; 279: F400-F416.
131. Michel JJ, Scott JD. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 2002, 42: 235-57.
132. Burns LL, Canaves JM, Pennypacker JK, Blumenthal DK, Taylor SS. Isoform specific differences in binding of a dual-specificity A-kinase anchoring protein to type I and type II regulatory subunit of PKA. Biochemistry 2003; 42: 5754-63.
133. de Rooji J, et al. Mechanisms of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem 2000 275: 20829-36.
134. Houslay MD, Milligan G. Tailoring cAMP signaling responses through isoform multiplicity. Trends Biochem Sci 1997 22: 217-24.
135. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchstrate signaling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370: 1-18.
136. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001; 41: 145-74.
137. Ishikawa Y. Isoform-targeted regulation of cardiac adenylyl cyclase. J Cradiovasc Pharmacol 2003; 41: S1-S4.
138. Patel TB, Du Z, Pierre S, Cartin L, Scholich K. Molecular biological approaches to unravel adenylyl cyclase signaling. Gene 2001; 269: 13-25.
139. Celano M, et al. Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol Cell Endocrinol 2003; 203: 129-35.
140. Baxendale RW, Fraser LR. Evidence for multiple distinctly localized adenylyl cyclase isoforms in mammalian spermatozoa. Mol Reprod Dev 2003; 66: 181-9.
141. Okumura S, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 2003; 100: 9986-90.
142. Johnson RA, et al. Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3′-polyphosphates. J Biol Chem 1997; 272: 8962-6.
143. Shoshani I, Laux WH, Perigaud C, Gosselin G, Johnson RA. Inhibition of adenylyl cyclase by acyclic nucleoside phosphonate antiviral agents. J Biol Chem 1999; 274: 34742-4.
144. Toya Y, Schwencke C, Ishikawa Y. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol 1998; 30: 97-108.
145. Onda T, et al. Type-specific Regulation of Adenylyl Cyclase. J Biol Chem 2001; 276: 47785-93.
146. Haunso A, Simpson J, Antoni FA. Small ligands modulating the activity of mammalian adenylyl cyclases: a novel mode of inhibition by calmidazolium. Mol Pharmacol 2003; 63: 624-31.
147. Torphy TJ. Phosphodiesterase Isozymes. Am J Respir Crit Care Med 1998; 157: 351-70.
148. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 1998; 95: 8991-6.
149. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 1999; 96: 7071-6.
150. Fawcett L, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000; 97: 3702-7.
151. Mehats C, Andersen CB, Filopanti M, Jin SLC, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrin Metab 2002; 13: 29-35.
152. Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C. Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling. J Biol Chem 2003; 278: 5493-6.
153. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8: 1255-96.
154. Keatings VM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-8.
155. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
156. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor. J Pharmacol Exp Ther 2001; 297: 280-90.
157. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, et al. SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions. J Pharmacol Exp Ther 1998; 284: 420-6.
158. Sturton G, Fitzgerald M. Phosphodiesterase 4 Inhibitors for the Treatment of COPD. Chest 2002; 121: 192S-6S.
159. Smith SJ, Brookes-Fazakerley S, Donnelly LE. Barnes PJ, Barnette MS, Giembycz MA. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2002; 294: L279-89.
160. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002; 128: 460-6.
161. Nehra A, Colreavy F, Khandheria BK, Chandrasekaran K. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. World J Urol 2001; 19: 40-5.
162. Ückert S, Küthe A, Stief CG, Jonas U. Phosphodiesterase isozymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 2001; 19: 14-22.
163. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signalling 2002; 14: 1-9.
164. Amieux PS, Howe DG, Knickerbocker H, Lee DC, Su T, Laslo GS, et al. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo, J Biol Chem 2002; 277: 27294-304.
165. Amieux PS, McKnight GS. The essential role of RI alpha in the maintenance of regulated PKA activity. Ann NY Acad Sci 2002; 968: 75-95.
166. Cho YSW, Cho-Chung YS. Antisense Protein Kinase A RIα Acts Synergistically with Hydroxycamptothecin to Inhibit Growth and Induce Apoptosis in Human Cancer Cells: Molecular Basis for Combinatorial Therapy. Clin Cancer Res 2003; 9: 1171-8.
167. Burns-Hamuro LL, et al. Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci USA 2003; 100: 4072-7.
168. Dent P, Grant S. Pharmacologic Interruption of the Mitogen- activated Extraceliular-regulated Kinase/Mitogen-activated Protein Kinase Signal Transduction Pathway: Potential Role in Promoting Cytotoxic Drug Action. Clin Cancer Res 2001; 7: 775-83.
169. Gianni L. The Future of Trageted Therapy: Combining Novel Agents. Oncology 2002; 63(suppl 1): 47-56.
170. Claria J. Cyclooxygenase-2 biology. Curr Pharm Design 2003; 9(27): 2177-90.
171. Frankel AE, Koo HM, Leppla SH, Duesbery NS, Wounde GF. Novel protein targeted therapy of metastatic melanoma. Curr Pharm Design 2003, 9(25): 2060-6.
172. Horvath TL, Castaneda T, Tang-Christensen M, Pagotto U, Tschop MH. Ghrelin as a potential anti-obesity target. Curr Pharm Design 2003; 9(17): 1383-95.